Sources and References

Primary textbook — Zierath, J.R., & Hawley, J.A. (Eds.) (2014). Skeletal Muscle Metabolism in Exercise and Diabetes. Springer. Mastaglia, F.L., & Laing, N.G. (Eds.) (2020). Muscle Disease: Pathology and Genetics, 3rd Edition. Wiley-Blackwell.

Supplementary texts — Lieber, R.L. (2010). Skeletal Muscle Structure, Function, and Plasticity, 3rd Edition. Lippincott Williams & Wilkins. Lynch, G.S. (Ed.) (2008). Sarcopenia — Age-Related Muscle Wasting and Weakness. Springer.

Online resources — PubMed (pubmed.ncbi.nlm.nih.gov); Journal of Physiology; American Journal of Physiology — Cell Physiology; Journal of Applied Physiology; Skeletal Muscle (BioMed Central); Neuromuscular Disorders (Elsevier); Nature Reviews Molecular Cell Biology; OMIM — Online Mendelian Inheritance in Man (omim.org) for genetic muscle diseases.

Chapter 1: Skeletal Muscle Structure and Function

Macroscopic and Microscopic Organization

Skeletal muscle is the largest organ by mass in the body, comprising approximately 40–45% of total body weight in healthy adult men and 35–40% in women. Its primary function — converting chemical energy from ATP hydrolysis into mechanical work — is fundamental to all voluntary movement, postural maintenance, thermoregulation (shivering thermogenesis), and serves as the body’s largest reservoir of protein and gluconeogenic amino acids during periods of metabolic stress. The study of skeletal muscle structure across hierarchical levels — from whole muscle to single protein — is prerequisite to understanding how this tissue fails in aging and disease.

At the whole muscle level, skeletal muscle is organized into discrete anatomical units — muscles like the biceps brachii, rectus femoris, or soleus — each with a characteristic origin and insertion, fiber arrangement (parallel, pennate, or bipennate), and functional role. Muscle architecture determines force-velocity relationships: parallel-fibered muscles (such as the sartorius) have long fibers relative to muscle length and are optimized for large excursion, while pennate muscles (such as the gastrocnemius) have fibers oriented at an angle to the line of pull and generate higher force per unit volume at the cost of reduced excursion. The physiological cross-sectional area (PCSA) — the cross-sectional area of the muscle perpendicular to the fiber direction, accounting for pennation angle — is proportional to maximum isometric force.

Each muscle is divided by connective tissue into fascicles (bundles of muscle fibers enclosed by perimysium), and each fascicle contains muscle fibers (individual muscle cells, or myofibers, enclosed by the endomysium). Muscle fibers are extraordinary cells: they are multinucleate (formed by the fusion of hundreds to thousands of myoblasts during development), can extend the entire length of the muscle in some cases (meters in large muscles), and are packed with the contractile machinery that constitutes their primary functional specialization. The plasma membrane of the muscle fiber is the sarcolemma; the cytoplasm (excluding the nucleus) is the sarcoplasm; and the modified endoplasmic reticulum — the sarcoplasmic reticulum (SR) — forms an elaborate network surrounding the myofibrils.

The Sarcomere: Molecular Architecture of Contraction

The protein components of the sarcomere are both numerous and exquisitely organized. The thick filaments (approximately 14 nm diameter, 1.6 μm length in human skeletal muscle) are bipolar assemblies of approximately 300 myosin II molecules, each consisting of two heavy chains (myosin heavy chain, MyHC) whose C-terminal regions intertwine to form the rod domain that constitutes the core of the thick filament, and two pairs of light chains (essential light chain, ELC; regulatory light chain, RLC) that associate with the N-terminal globular motor domain (S1 subfragment) of each heavy chain. The motor domain contains the actin-binding site and the ATP hydrolysis site that drives the cross-bridge cycle — the mechanochemical cycle of actin binding, force generation (power stroke), ADP and Pi release, ATP binding, and detachment that is the molecular basis of muscle contraction.

The thin filaments (approximately 7 nm diameter, 1.0 μm long from the Z-disc) are helical polymers of filamentous actin (F-actin, assembled from globular G-actin monomers), decorated at regular intervals by the troponin-tropomyosin regulatory complex. Tropomyosin is a coiled-coil dimer that lies in the groove of the actin double helix and, at resting calcium concentrations, sterically blocks the myosin-binding sites on actin, preventing cross-bridge formation. The troponin complex consists of three subunits: troponin C (TnC), the calcium-binding subunit; troponin I (TnI), the inhibitory subunit that stabilizes the blocked configuration of tropomyosin; and troponin T (TnT), which anchors the complex to tropomyosin. When intracellular calcium rises above approximately 0.5 μM (from its resting level of approximately 0.1 μM), four calcium ions bind to TnC’s low-affinity N-terminal sites, inducing a conformational change transmitted to TnI and tropomyosin, shifting tropomyosin laterally to expose the myosin-binding sites on actin and permitting cross-bridge formation.

Titin is the largest protein known, spanning from the Z-disc to the M-line in the center of the sarcomere (a single molecule approximately 1 μm long when stretched), and functions as a molecular spring and scaffold. The I-band portion of titin (between the Z-disc and the edge of the thick filament) contains tandem immunoglobulin domains and the PEVK region (rich in proline, glutamate, valine, and lysine), which extend under passive stretch and provide the passive tension that resists over-extension of the sarcomere and ensures centering of the thick filament. Titin also serves as a mechanosensor: phosphorylation of its N2B and PEVK regions by signaling kinases (PKA, PKC, ERK2, CaMKII) modifies titin’s elastic properties in response to mechanical loading, providing a mechanism for the muscle to adapt its passive mechanics to its loading history. Titin mutations — particularly in the A-band domain — are the most common cause of familial dilated cardiomyopathy and cause limb-girdle muscular dystrophy type 2J.

Fiber Types and Contractile Properties

Adult human skeletal muscle contains a spectrum of fiber types distinguished by the isoform of myosin heavy chain expressed: type I (slow-oxidative, expressing MyHC-I/β), type IIa (fast-oxidative-glycolytic, expressing MyHC-IIa), and type IIx (fast-glycolytic, expressing MyHC-IIx, previously called IId in rat muscle). A fourth isoform, MyHC-IIb, is the fastest and is expressed in small mammals but not in adult human skeletal muscle except in certain jaw muscles. The MyHC isoform determines the kinetics of the cross-bridge cycle: the ATPase rate of myosin increases in the order I < IIa < IIx < IIb, governing the maximal shortening velocity (V_max) of the fiber.

Type I fibers are characterized by high mitochondrial content and oxidative enzyme activity, high myoglobin content (giving them a red color), small diameter, low specific tension (force per cross-sectional area), high fatigue resistance, and slow twitch kinetics. They are recruited preferentially during low-intensity, sustained activities (postural maintenance, walking). Type IIa fibers are intermediate, combining substantial mitochondrial capacity with faster twitch kinetics and higher specific tension; they are recruited for moderate to high intensity exercise. Type IIx fibers have low mitochondrial content, fast twitch kinetics, very high specific tension, and fatigue rapidly; they are recruited during maximal efforts. The concept of orderly motor unit recruitment (Henneman’s size principle) states that within a motor unit pool serving a muscle, motor units are recruited in order of increasing motor neuron size — small, slow type I motor units first, then intermediate type IIa units, then large, fast type IIx units — as the force demand increases.

Excitation-Contraction Coupling

Excitation-contraction coupling (ECC) is the sequence of events linking the electrical signal (action potential) at the motor nerve terminal to the mechanical response (cross-bridge formation and force development) within the sarcomere. It is one of the most precisely coordinated signaling processes in mammalian physiology and involves the interplay of voltage sensors, calcium release channels, and the sarcoplasmic reticulum calcium store.

The sequence of events in ECC is as follows. An action potential propagates along the motor axon and triggers acetylcholine (ACh) release from the presynaptic terminal at the neuromuscular junction (NMJ). ACh binds nicotinic ACh receptors (nAChR) at the postsynaptic end-plate, producing an endplate potential that depolarizes the sarcolemma and initiates an action potential. The action potential propagates along the sarcolemma and down into the transverse tubules (T-tubules) — narrow membrane invaginations that penetrate deep into the fiber and approach within nanometers of the SR terminal cisternae, forming the triad (one T-tubule flanked by two SR terminal cisternae). In the triad, dihydropyridine receptors (DHPR) in the T-tubule membrane function as voltage sensors, detecting depolarization of the T-tubule membrane. In skeletal muscle, DHPR are mechanically coupled — through direct protein-protein interactions — to the ryanodine receptor type 1 (RyR1) in the SR membrane. Voltage-induced conformational changes in DHPR are transmitted mechanically to RyR1, opening the RyR1 channel and allowing Ca2+ to flow down its electrochemical gradient from the SR lumen (where Ca2+ concentration is approximately 1 mM) into the sarcoplasm (raising cytosolic Ca2+ from approximately 100 nM at rest to 10–100 μM during activation).

Released calcium binds TnC, tropomyosin moves, and cross-bridge cycling commences. Upon cessation of the action potential train, DHPR closes, RyR1 closes, and SR Ca2+-ATPase (SERCA) pumps — primarily SERCA1 in fast-twitch fibers and SERCA2 in slow-twitch fibers — actively transport Ca2+ back into the SR lumen against its concentration gradient, restoring cytosolic Ca2+ to resting levels and allowing troponin-tropomyosin to re-block the actin-binding sites, terminating contraction (muscle relaxation).

Chapter 2: Skeletal Muscle Development and Aging

Muscle Development: From Myoblast to Mature Fiber

The development of skeletal muscle — myogenesis — is a precisely orchestrated process involving the specification, proliferation, differentiation, and fusion of myogenic progenitor cells. Understanding myogenesis is essential background for understanding satellite cell biology (the cellular basis of muscle regeneration) and for interpreting the molecular defects in congenital muscular dystrophies.

Embryonic myogenesis begins with the specification of mesodermal precursors in the somites as myogenic precursor cells. This specification is controlled by the PAX3/PAX7 family of transcription factors (which maintain cells in a progenitor state) and the myogenic regulatory factors (MRFs) — a family of basic helix-loop-helix (bHLH) transcription factors comprising MyoD, Myf5, MRF4 (Myf6), and myogenin. MyoD and Myf5 function as “determination” factors — their expression commits cells to the skeletal muscle lineage; myogenin and MRF4 function as “differentiation” factors that drive terminal differentiation, including the upregulation of muscle-specific structural genes (MyHC isoforms, actin, troponin, titin). MRF knockout studies in mice have elucidated the partially redundant and complementary roles of these factors: MyoD null mice have markedly reduced myogenin-expressing myoblasts in limb muscle (Myf5 compensates in the trunk), and myogenin null mice die at birth from an inability to differentiate myoblasts into myotubes despite normal myoblast specification. The MRFs function in concert with members of the MEF2 (myocyte enhancer factor 2) family of MADS-box transcription factors, which cooperate with MRFs to amplify the myogenic transcriptional program.

Once myoblasts are committed, they proliferate extensively, then undergo terminal differentiation — withdrawal from the cell cycle (irreversible cell cycle arrest), upregulation of muscle-specific genes, and fusion to form multinucleated myotubes. The fusion process requires the sequential activity of several membrane proteins including MYOMIXER (Minion), MYOMAKER, and MRTF-A/SRF, and involves calcium-dependent membrane restructuring. Failure of the fusion process — due to mutations in MYOMAKER — produces a form of congenital myopathy characterized by myotubes that fail to mature into myofibers.

Aging Muscle: Mechanisms of Sarcopenia

Sarcopenia — the progressive, age-related loss of skeletal muscle mass, strength, and functional capacity — begins at approximately age 40 and accelerates markedly after age 65–70. By age 80, individuals typically retain only 60–70% of the peak muscle mass achieved in young adulthood, with losses most pronounced in the lower extremity muscles critical for locomotion and fall prevention. The functional consequence of sarcopenia — reduced strength, power, and endurance, with impaired balance and gait — is the primary mediator of the loss of independence, increased fall risk, and elevated mortality associated with advanced aging.

At the cellular level, sarcopenia results from an imbalance between the rates of muscle protein synthesis (MPS) and muscle protein breakdown (MPB), with MPB exceeding MPS over prolonged time periods. This imbalance arises from anabolic resistance — the reduced sensitivity of aging muscle protein synthetic machinery to the stimuli (amino acids, insulin, IGF-1, mechanical load) that normally activate MPS through the mTORC1 pathway. The mechanistic basis of anabolic resistance is incompletely understood but likely involves: reduced mTORC1 signaling in response to leucine; impaired insulin receptor substrate (IRS-1) phosphorylation; accumulation of ceramides and diacylglycerol in muscle (from intramyocellular lipid infiltration) that activate PKC-theta and impair insulin-PI3K-Akt signaling; and reduced expression of amino acid sensing proteins (particularly SESN1, SESN2 — sensors of leucine that activate the GATOR2 complex to signal to mTORC1).

At the fiber level, sarcopenia is characterized by preferential loss of type II (fast-twitch) fibers, particularly type IIx, resulting in a shift toward a more type-I-predominant muscle phenotype that is relatively slower and less powerful but more fatigue-resistant. This selective type II fiber loss reflects the progressive loss of fast-twitch motor neurons with aging — denervation of type IIx fibers is followed by either reinnervation by slow-twitch axons (producing fiber-type conversion) or fiber atrophy and eventual death if reinnervation does not occur. The neuromuscular junction (NMJ) also undergoes progressive deterioration with aging: NMJ area increases (axonal sprouting), the postsynaptic acetylcholine receptor clusters become fragmented, and neurotransmission becomes less reliable, contributing to “jitter” (variability in the delay between motor nerve action potential and muscle fiber action potential) detectable by single-fiber EMG.

Chapter 3: Skeletal Muscle Adaptations to Disease

Duchenne Muscular Dystrophy: Molecular Pathology

The DMD gene is the largest gene in the human genome (2.5 megabases, 79 exons), which partly explains its high mutation rate. Approximately 65% of DMD mutations are large deletions of one or more exons, 10% are large duplications, and the remainder are point mutations, small deletions or insertions, or splice site mutations. The key concept for understanding the genotype-phenotype relationship in dystrophin disorders is the reading frame rule: mutations that disrupt the reading frame (frameshift mutations) lead to a premature stop codon and loss of full-length dystrophin protein, producing the severe DMD phenotype; mutations that maintain the reading frame (in-frame deletions or duplications) allow production of an internally truncated but partially functional dystrophin protein, producing the milder Becker muscular dystrophy (BMD) phenotype. This distinction has direct therapeutic implications: exon-skipping therapies (antisense oligonucleotides that cause the spliceosome to skip one or more exons, converting an out-of-frame to an in-frame deletion and allowing production of a Becker-like truncated dystrophin) are designed to convert DMD to the milder BMD phenotype.

Dystrophin is a 427 kDa cytoskeletal protein located at the inner surface of the sarcolemma, connecting the intracellular actin cytoskeleton (via its N-terminal actin-binding domain) to the extracellular matrix (via its C-terminal association with the dystrophin-associated protein complex (DAPC), which includes dystroglycans, sarcoglycans, syntrophins, and dystrobrevin). This transmembrane linkage — the costamere — provides mechanical stability to the sarcolemma during contraction, distributing the lateral forces of sarcomere shortening uniformly across the plasma membrane rather than concentrating them at discrete points. In the absence of dystrophin, the costamere is disrupted: the sarcolemma is mechanically fragile and susceptible to tearing (membrane disruption) during contraction, particularly eccentric contractions that place maximal mechanical stress on the sarcolemma.

Sarcolemmal disruption allows uncontrolled calcium influx from the extracellular space into the cytoplasm, triggering a cascade of downstream pathology: calcium-activated protease (calpain) activity degrades cytoskeletal and myofibrillar proteins; mitochondrial calcium overload disrupts oxidative phosphorylation and can trigger mitochondrial permeability transition pore (mPTP) opening and release of cytochrome c (initiating apoptosis); activation of NF-κB by calcium-mediated signaling drives chronic inflammatory gene expression; and repeated cycles of membrane disruption, necrosis, and regeneration eventually exhaust the regenerative capacity of the satellite cell population. In the muscle of young DMD patients (before regenerative failure), histology demonstrates a characteristic pattern of ongoing necrosis (eosinophilic, degenerating fibers infiltrated by macrophages), ongoing regeneration (basophilic, centrally-nucleated small fibers), and inflammatory infiltration (primarily neutrophils acutely, then macrophages and CD4+ T cells). In older patients, this cycle gives way to progressive fibrotic replacement and fatty infiltration as satellite cell regenerative capacity is exhausted.

Mitochondrial Myopathies

Mitochondrial myopathies are a heterogeneous group of disorders caused by mutations in either the mitochondrial genome (mtDNA) or nuclear genes encoding proteins required for mitochondrial function. They collectively constitute one of the most common groups of genetic neuromuscular diseases, with combined prevalence of pathogenic mtDNA variants of approximately 1 in 5,000 and nuclear mitochondrial gene variants at a similar prevalence.

The mitochondrial genome is a circular, 16.6 kilobase double-stranded DNA molecule present in multiple copies per mitochondrion (typically 2–10) and thousands of copies per cell. It encodes 13 proteins (all subunits of the oxidative phosphorylation complexes I, III, IV, and V), 22 transfer RNAs, and 2 ribosomal RNAs required for mitochondrial translation of these 13 proteins. All other mitochondrial proteins (approximately 1,500) are encoded by nuclear DNA, synthesized on cytoplasmic ribosomes, and imported into the mitochondrion via the translocase of the outer membrane (TOM) and translocase of the inner membrane (TIM) complexes. Mutations in either the 13 mtDNA-encoded subunits or the approximately 100 nuclear-encoded OXPHOS subunits and their assembly factors can cause mitochondrial disease.

Heteroplasmy — the coexistence of mutant and wild-type mtDNA within the same cell — is a key concept in understanding the variable expressivity of mtDNA mutations. Because mitochondria are maternally inherited and segregate randomly at cell division, the proportion of mutant mtDNA may vary between tissues and between family members carrying the same maternal mutation. A threshold effect operates: below a certain percentage of mutant mtDNA (which varies by mutation and by tissue, reflecting tissue-specific energy demands), sufficient normal OXPHOS function is maintained and no clinical manifestation occurs. Above the threshold, OXPHOS failure produces cellular dysfunction that is most severe in highly energy-demanding tissues — skeletal muscle, heart, brain, and retina — explaining the classic clinical features of mitochondrial myopathy (weakness, exercise intolerance), cardiomyopathy, encephalopathy (particularly stroke-like episodes in MELAS — Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes), and ophthalmoplegia (external ophthalmoplegias and retinal dystrophy in Kearns-Sayre syndrome and chronic progressive external ophthalmoplegia, CPEO).

Heart Failure and COPD: Skeletal Muscle Implications

Skeletal muscle dysfunction is a major contributor to exercise intolerance in patients with heart failure and chronic obstructive pulmonary disease (COPD) — two of the most prevalent and debilitating chronic diseases in the aging population. Understanding the mechanisms by which these systemic diseases alter skeletal muscle biology is essential for developing effective rehabilitation interventions.

In heart failure, skeletal muscle pathology includes: fiber type shift (loss of type I fibers, shift toward type IIx); reduced mitochondrial content and oxidative enzyme activity; impaired microvascular density (reduced capillary-to-fiber ratio); increased expression of atrophy-related ubiquitin ligases (MuRF1, Atrogin-1); and elevated circulating pro-inflammatory cytokines (particularly TNF-alpha, IL-1beta, IL-6) from the failing myocardium and from increased intestinal permeability. These changes reduce the oxidative capacity of the muscle, increasing reliance on glycolytic metabolism and accelerating fatigue at submaximal exercise intensities. The degree of skeletal muscle dysfunction in heart failure is a strong predictor of exercise capacity (peak VO2), hospitalizations, and mortality, independently of measures of cardiac function — a finding that has established skeletal muscle as a therapeutic target in heart failure management.

In COPD, skeletal muscle pathology is broadly similar to that in heart failure, though with additional contributions from: hypoxemia (reduced oxygen delivery to muscle during exercise, impairing aerobic metabolism); hypercapnia (respiratory acidosis); elevated systemic glucocorticoids (from exacerbation treatment, activating muscle atrophy pathways); and severe physical deconditioning from activity limitation imposed by dyspnea. Peripheral muscle dysfunction — particularly of the quadriceps, which bears the greatest burden during walking — is a better predictor of mortality in COPD than FEV1 (the standard measure of airflow limitation). Pulmonary rehabilitation — the combination of supervised exercise training, education, and nutritional support — improves exercise tolerance, quality of life, and healthcare utilization in COPD patients through its effects on both cardiovascular fitness and peripheral muscle function.

Chapter 4: Satellite Cells and Muscle Regeneration

Satellite Cell Biology and Niche

Satellite cells express the transcription factor PAX7 constitutively — this is the defining molecular marker of the satellite cell lineage, used to identify satellite cells immunohistochemically. In quiescent satellite cells, PAX7 suppresses myogenic differentiation by promoting the expression of factors that inhibit MyoD transcriptional activity. Upon activation (by muscle damage, growth factors, or Notch signaling), satellite cells upregulate both PAX7 and MYOD, entering a proliferative state. Asymmetric cell divisions produce two types of daughter cells: those that retain high PAX7 and downregulate MyoD return to quiescence, replenishing the satellite cell pool; those that downregulate PAX7 and maintain MyoD expression commit to differentiation, eventually fusing with existing fibers or forming new myotubes to repair damaged areas.

The satellite cell niche — the microenvironmental context in which satellite cells reside — profoundly regulates their quiescence, activation, and differentiation. Key niche components include: the basal lamina (providing structural support and sequestering growth factors including IGF-1, FGF2, and HGF that regulate satellite cell activity); the muscle fiber itself (which provides mechanical and paracrine signals — notably Notch ligands presented on the fiber surface); interstitial cells (FAPs — fibro-adipogenic progenitors — which produce extracellular matrix and growth factors that regulate satellite cell behavior); immune cells (macrophages transition from a pro-inflammatory M1 phenotype that promotes necrosis clearance to an anti-inflammatory M2 phenotype that secretes IGF-1 and promotes satellite cell differentiation during the course of repair); and the systemic circulation (providing endocrine signals including IGF-1, testosterone, and cortisol that regulate satellite cell activity).

Satellite Cell Dysfunction in Aging and Disease

The satellite cell pool declines progressively with aging: satellite cells in aging muscle are fewer in number (particularly associated with type II fibers), less readily activated from quiescence, and show reduced self-renewal capacity. Multiple mechanisms contribute to age-related satellite cell dysfunction. Intrinsically, aging satellite cells accumulate DNA damage (including double-strand breaks that impair proliferation), exhibit reduced chromatin accessibility at myogenic gene loci (reflecting age-related epigenetic silencing), and show increased expression of cell cycle inhibitors (p16^INK4a, p21^Cip1) that restrain proliferation. Extrinsically, the aging niche provides reduced IGF-1, altered Notch and Wnt signaling balance, chronic inflammation (elevated TNF-alpha, TGF-beta), and increased extracellular matrix stiffness — all of which impair satellite cell function.

The landmark parabiosis experiments of Amy Wagers and colleagues, in which the circulatory systems of young and old mice were surgically joined (heterochronic parabiosis), demonstrated that blood-borne factors from young mice could rejuvenate satellite cell function in old mice, while factors from old mice impaired satellite cell function in young mice. This provided direct evidence that the aged systemic environment, not intrinsic aging of satellite cells per se, is the primary driver of satellite cell functional decline — and suggested that identifying and targeting circulating inhibitory factors could offer therapeutic strategies for preserving satellite cell function with aging. Subsequent work has identified GDF11 (growth differentiation factor 11) and GDF8 (myostatin) as circulating factors whose dysregulation may contribute to muscle aging, though the biology of GDF11 has proven controversial, and Wnt-induced signaling protein 1 (WISP1) as a young-blood factor that promotes satellite cell asymmetric division and self-renewal.

Chapter 5: Mitochondria in Skeletal Muscle

Mitochondrial Structure, Dynamics, and Biogenesis

Mitochondria in skeletal muscle are far more complex than the textbook “powerhouse” depiction suggests. They form a dynamic, interconnected network — the mitochondrial reticulum — that changes size and connectivity in response to energetic demand, cellular stress, and the balance of fusion and fission. In skeletal muscle, mitochondria are present as two anatomically and functionally distinct populations: subsarcolemmal mitochondria (SSM), located beneath the sarcolemma and enriched in electron transport chain (ETC) complexes; and intermyofibrillar mitochondria (IMF), located between myofibrils in close contact with sites of ATP demand (the sarcoplasmic reticulum) and calcium release (the SR terminal cisternae).

Mitochondrial fusion — the joining of two mitochondria into one — is driven by the GTPase proteins MFN1 and MFN2 (mitofusins, which mediate outer membrane fusion) and OPA1 (optic atrophy protein 1, which mediates inner membrane fusion). Fusion allows mitochondria to share matrix contents (proteins, mtDNA, metabolites) — providing a mechanism for damaged mitochondria to complement each other’s deficiencies and maintain function. Mitochondrial fission — division of a mitochondrion into two — is driven primarily by DRP1 (dynamin-related protein 1), a cytoplasmic GTPase that is recruited to outer membrane receptors (MFF, FIS1, MiD49/51), assembles into spiral oligomers around the mitochondrion, and constricts the membrane in a GTP hydrolysis-dependent manner. Fission generates small mitochondrial fragments that are either degraded by mitophagy (if depolarized and dysfunctional) or incorporated into the reticular network (if healthy).

Mitochondrial biogenesis — the synthesis of new mitochondrial components and the expansion of the mitochondrial mass — is regulated primarily by the transcriptional co-activator PGC-1alpha (peroxisome proliferator-activated receptor gamma co-activator 1-alpha). PGC-1alpha is a master regulator of mitochondrial biogenesis and oxidative metabolism: it co-activates nuclear receptors (PPARalpha, PPARgamma) and transcription factors (NRF1, NRF2) that drive expression of nuclear-encoded mitochondrial genes, and it co-activates TFAM (mitochondrial transcription factor A) to drive mtDNA transcription and replication. PGC-1alpha is strongly upregulated in skeletal muscle by exercise (through AMPK activation, which phosphorylates and activates PGC-1alpha, and through calcium/CaMKII signaling), by cold exposure (via beta-adrenergic signaling), and by caloric restriction. Loss of PGC-1alpha expression in aging skeletal muscle — associated with reduced AMPK activity — is a major contributor to the decline in mitochondrial content, oxidative capacity, and exercise tolerance that accompanies sarcopenia.

Mitochondrial Dysfunction in Aging and Disease

Aging skeletal muscle is characterized by progressive mitochondrial dysfunction, manifesting as reduced electron transport chain (ETC) complex activities, reduced mitochondrial ATP synthesis rates, increased production of reactive oxygen species (ROS), reduced mitochondrial membrane potential, and increased accumulation of somatic mtDNA mutations. These changes are particularly prominent in electron transport chain complexes containing mtDNA-encoded subunits (complexes I, III, and IV), suggesting that somatic mtDNA mutations — which accumulate with age due to the proximity of mtDNA to ROS generated during OXPHOS and the limited mtDNA repair capacity — are a significant contributor to age-related OXPHOS dysfunction.

A key feature of age-related mitochondrial dysfunction is the impairment of mitochondrial quality control. The mitophagy pathway — selective autophagic degradation of dysfunctional mitochondria — requires the selective cargo receptors NDP52, OPTN, and p62/SQSTM1 to tether ubiquitinated outer mitochondrial membrane proteins to the autophagosome, which fuses with the lysosome for degradation. A critical regulator of mitophagy is the PINK1-Parkin pathway: PINK1 (a kinase) accumulates on the outer membrane of depolarized mitochondria (on healthy mitochondria, PINK1 is imported and cleaved; on damaged mitochondria, impaired import allows PINK1 accumulation and stabilization), where it phosphorylates ubiquitin and Parkin (an E3 ubiquitin ligase), activating Parkin’s ligase activity and driving ubiquitination of outer mitochondrial membrane proteins that serve as mitophagy signals. In aging muscle, PINK1 and Parkin expression decline, and mitophagy efficiency is reduced, allowing dysfunctional mitochondria to accumulate rather than being efficiently cleared — contributing to the progressive deterioration of mitochondrial network quality.

Chapter 6: Free Radicals and Oxidative Stress in Skeletal Muscle

Reactive Oxygen Species: Sources and Chemistry

The primary source of ROS in skeletal muscle is the mitochondrial electron transport chain, particularly at complexes I and III, where incomplete reduction of oxygen produces superoxide as a by-product of normal electron flow. Approximately 0.1–2% of electrons flowing through the ETC “leak” to oxygen, generating superoxide rather than contributing to the proton gradient that drives ATP synthesis. The rate of superoxide production is proportional to the mitochondrial membrane potential (the proton gradient force) and inversely proportional to the efficiency of electron flow — conditions that increase the reduced state of ETC carriers (such as high NAD(P)H/NAD+ ratios, as occur during high-fat feeding or during the transition from exercise to rest) increase ROS production.

Non-mitochondrial sources of ROS in skeletal muscle include NADPH oxidase complexes (NOX2 and NOX4), which transfer electrons from NADPH to oxygen to produce superoxide — a reaction that is activated by mechanical stretch, growth factors, and inflammatory cytokines; xanthine oxidase, which produces uric acid from hypoxanthine and generates superoxide and H2O2 in the process; and phospholipase A2-mediated arachidonic acid release, which can generate lipid radicals. During exercise, ROS production is elevated from multiple sources — mitochondrial (from increased flux through the ETC), from NOX2 (activated by calcium and mechanical stimuli at the T-tubule), and from xanthine oxidase (upregulated by ischemia-reperfusion cycles during high-intensity exercise).

Antioxidant Defense Systems and Oxidative Stress Signaling

Skeletal muscle possesses a hierarchy of antioxidant defense systems that scavenge or neutralize ROS before they cause oxidative damage. Enzymatic antioxidants include: superoxide dismutases (SODs), which catalyze the dismutation of superoxide to H2O2 (the cytoplasmic form, Cu/Zn-SOD encoded by SOD1; the mitochondrial form, Mn-SOD encoded by SOD2; and the extracellular form, EC-SOD encoded by SOD3); catalase, which converts H2O2 to water and oxygen (present in peroxisomes and cytoplasm); and the glutathione peroxidase (GPx) family, which reduces H2O2 and lipid hydroperoxides using reduced glutathione (GSH) as the electron donor, converting them to water (and GSH to GSSG). The thioredoxin/thioredoxin reductase system and the peroxiredoxin family provide additional H2O2-scavenging capacity.

A critical concept in redox biology is the distinction between oxidative eustress (physiological, adaptive ROS signaling) and oxidative distress (excessive, indiscriminate ROS damage). During acute exercise, ROS serve as important signaling molecules that activate adaptive pathways: H2O2 activates Nrf2 (nuclear factor erythroid 2-related factor 2), the master transcriptional regulator of the antioxidant response — Nrf2 is normally kept cytoplasmic by its binding partner Keap1, but oxidation of Keap1 cysteine residues releases Nrf2 to translocate to the nucleus and activate antioxidant response element (ARE)-driven genes (including SOD2, catalase, GPx1, heme oxygenase-1, and glutamate-cysteine ligase for GSH synthesis). This exercise-induced Nrf2 activation drives an upregulation of antioxidant defenses that persists beyond the exercise bout, increasing the muscle’s resistance to subsequent oxidative challenge.

In aging and chronic disease (heart failure, COPD, diabetes), the balance shifts toward chronic oxidative distress: ROS production is persistently elevated (from increased mitochondrial leak, increased NOX2 activity from chronic inflammation, and increased xanthine oxidase from uric acid metabolism), while antioxidant defenses are impaired (reduced GSH, reduced Nrf2 activity). Chronic oxidative damage accumulates in proteins (carbonylation, nitration, cysteine oxidation), lipids (peroxidation, generating 4-hydroxynonenal and malondialdehyde that form protein adducts), and DNA (8-oxoguanine, strand breaks). Protein carbonylation and 4-HNE adducts mark proteins for proteasomal degradation; widespread protein carbonylation in aging muscle reflects both increased ROS production and impaired proteasomal clearance capacity.

Chapter 7: Apoptosis and Cell Death in Skeletal Muscle

Intrinsic and Extrinsic Apoptosis Pathways

Apoptosis is executed by caspases — a family of cysteine-aspartate proteases that exist as inactive zymogens (procaspases) and are activated by proteolytic cleavage during apoptosis. Initiator caspases (caspase-8, caspase-9) are activated upstream by specific molecular platforms; executioner caspases (caspase-3, caspase-6, caspase-7) are cleaved and activated by initiator caspases and directly execute the biochemical hallmarks of apoptosis (DNA laddering by caspase-activated DNase, CAD; cleavage of structural proteins; phosphatidylserine externalization to the outer leaflet of the plasma membrane).

The intrinsic (mitochondrial) pathway is activated by cellular stressors — DNA damage, oxidative stress, endoplasmic reticulum stress, growth factor withdrawal — that converge on the Bcl-2 family of proteins, which regulate mitochondrial outer membrane permeability. Pro-apoptotic Bcl-2 family members (Bax, Bak, Bad, Bid, Bim, PUMA, Noxa) promote mitochondrial outer membrane permeabilization (MOMP); anti-apoptotic members (Bcl-2, Bcl-xL, Mcl-1) inhibit MOMP by binding and sequestering pro-apoptotic members. When pro-apoptotic signals predominate, Bax and Bak undergo conformational changes, oligomerize, and form pores in the outer mitochondrial membrane — releasing cytochrome c into the cytoplasm, where it assembles with Apaf-1 and procaspase-9 to form the apoptosome — the molecular platform that cleaves and activates caspase-9. Caspase-9 then activates caspase-3, initiating the execution phase of apoptosis.

The extrinsic (death receptor) pathway is initiated by binding of death ligands (FasL, TNF-alpha, TRAIL) to their cognate death receptors (Fas/CD95, TNFR1, DR4/DR5). Ligand binding induces receptor oligomerization and recruitment of the adapter protein FADD (Fas-associated death domain), which recruits procaspase-8 to form the death-inducing signaling complex (DISC), where caspase-8 is activated. Caspase-8 can directly activate caspase-3 (in type I cells with high caspase-8 activation) or cleave Bid to truncated Bid (tBid), which activates the intrinsic pathway through Bax/Bak activation (in type II cells, including most skeletal muscle fibers, where direct caspase-8 activation is insufficient to activate caspase-3 directly).

Apoptosis in Aging Skeletal Muscle

The rate of myonuclear apoptosis is elevated in aging skeletal muscle compared to young muscle, and this increased apoptotic rate contributes to sarcopenia through two potential mechanisms: direct loss of myonuclei (which, if not compensated by satellite cell-derived nuclear addition, reduces the transcriptional capacity of the fiber and may trigger atrophy); and as one manifestation of a broader shift in the balance of pro- and anti-survival signaling in aging muscle.

Aged skeletal muscle shows elevated expression of pro-apoptotic proteins (Bax, FasL, caspase-3, caspase-9, cytochrome c in the cytoplasm) and reduced expression of anti-apoptotic proteins (Bcl-2, Bcl-xL), indicating a shift toward greater apoptotic sensitivity. The elevated cytoplasmic cytochrome c observed in aging muscle likely reflects increased mitochondrial permeability due to the chronic oxidative stress and reduced integrity of the mitochondrial outer membrane. TUNEL staining (which labels DNA fragmentation) in aged skeletal muscle consistently shows 2–5-fold higher rates of positive nuclei compared to young muscle. Importantly, these apoptotic nuclei are predominantly located in the subsarcolemmal region rather than centrally — a pattern consistent with mitochondrially-derived apoptotic signals emanating from the subsarcolemmal mitochondria.

The role of inflammation in age-related apoptosis is particularly important: elevated TNF-alpha in aging muscle activates the extrinsic death receptor pathway through TNFR1, increasing FasL-Fas interaction and DISC formation. Blocking TNF-alpha signaling with soluble TNF receptors or anti-TNF antibodies (the mechanism of action of rheumatoid arthritis drugs like etanercept and adalimumab) reduces apoptosis and preserves muscle mass in rodent models of aging, suggesting that TNF-alpha-driven apoptosis is a viable therapeutic target for sarcopenia.

Chapter 8: Cellular Degradation and Autophagy in Skeletal Muscle

The Ubiquitin-Proteasome System

The two principal pathways for intracellular protein degradation in skeletal muscle are the ubiquitin-proteasome system (UPS) and autophagy-lysosomal pathway (ALP). Both pathways are critical for maintaining proteostasis — the quality control of the proteome by clearing damaged, misfolded, and excess proteins — and both are dysregulated in sarcopenia and myopathic states.

The UPS degrades individual proteins through a three-step cascade: ubiquitin activating enzyme (E1) activates ubiquitin (a 76-amino acid protein that serves as a degradation tag) in an ATP-dependent reaction; ubiquitin conjugating enzyme (E2) receives ubiquitin from E1 and transfers it to the substrate-bound E3; and ubiquitin ligase (E3) catalyzes the transfer of ubiquitin from E2 to a lysine residue of the substrate protein, creating an isopeptide bond. Repetition of this cycle, using K48 linkages between ubiquitin molecules, builds a polyubiquitin chain of at least four ubiquitins that is recognized by the 26S proteasome — a large proteolytic complex consisting of the barrel-shaped 20S core particle (which performs the actual proteolysis) capped at one or both ends by the 19S regulatory particle (which recognizes polyubiquitin chains, removes them, and unfolds substrates for insertion into the proteolytic core).

Two E3 ubiquitin ligases are particularly important in skeletal muscle atrophy: MuRF1 (Muscle RING finger 1, encoded by Trim63) and Atrogin-1 (also called MAFbx, encoded by Fbxo32). Both were identified simultaneously in 2001 as genes dramatically upregulated in multiple models of skeletal muscle atrophy (denervation, unloading, fasting, glucocorticoid treatment) — their discovery established the molecular concept of atrophy-related ubiquitin ligases (atrogenes). MuRF1 is localized at the sarcomere M-band and Z-disc and ubiquitinates MyHC (targeting thick filaments for degradation), titin, and troponin I — explaining how the atrophy program selectively dismantles the contractile apparatus. Atrogin-1 ubiquitinates eIF3-f (a translation initiation factor, thereby suppressing protein synthesis) and MyoD (targeting the differentiation program), in addition to structural proteins.

The transcriptional regulators of MuRF1 and Atrogin-1 are the FoxO family transcription factors (FoxO1, FoxO3, and FoxO4), which bind to FOXO response elements in the promoters of MuRF1 and Atrogin-1 and drive their transcription. FoxO activity is suppressed by the PI3K/Akt signaling pathway: when Akt is active (as it is in response to IGF-1, insulin, or mechanical loading), it phosphorylates FoxO proteins on three specific residues, sequestering them in the cytoplasm and preventing them from entering the nucleus to drive atrogene transcription. When Akt activity falls (in states of nutrient deprivation, inflammation, disuse, or aging), FoxO proteins dephosphorylate and translocate to the nucleus, driving MuRF1 and Atrogin-1 expression. This FoxO-MuRF1/Atrogin-1 axis is the molecular mechanism by which the Akt pathway controls the balance between muscle protein synthesis (anabolic) and degradation (catabolic) — making it one of the most important signaling nodes in muscle biology.

Autophagy in Muscle Homeostasis and Disease

Autophagy is a process of lysosome-mediated intracellular degradation that handles substrates the proteasome cannot: large protein aggregates, organelles (mitochondria via mitophagy, peroxisomes via pexophagy, ER via reticulophagy), lipid droplets (lipophagy), pathogens (xenophagy), and glycogen (glycophagy). In skeletal muscle, autophagy is essential for maintaining proteostasis, clearing damaged organelles, and providing amino acids during nutrient deprivation.

The molecular machinery of autophagy (the ATG proteins) orchestrates the formation of a double-membrane isolation membrane (phagophore), its expansion and closure to form the autophagosome (which sequesters substrates), and the autophagosome-lysosome fusion that generates the autolysosome where lysosomal hydrolases degrade the sequestered contents. The master regulator of autophagy initiation is ULK1 (the mammalian homolog of yeast ATG1): when activated by energy deficit (AMPK phosphorylation) or growth factor withdrawal (mTORC1 suppression, releasing its inhibitory phosphorylation of ULK1), ULK1 initiates the autophagy cascade by phosphorylating and activating the VPS34-Beclin1-ATG14 PI3K complex that generates PI3P at the phagophore membrane. Two ubiquitin-like conjugation systems (the ATG12-ATG5-ATG16L1 system and the LC3-PE conjugation system) drive membrane elongation and closure.

Selective autophagy relies on autophagy cargo receptors — p62/SQSTM1, NBR1, NDP52, OPTN, and others — that simultaneously bind ubiquitinated cargo and the autophagosomal membrane protein LC3 (through LC3-interaction regions, LIRs), tethering specific substrates to the growing autophagosome. In muscle, selective mitophagy via the PINK1-Parkin-p62 axis (described above) and selective aggrephagy (clearance of protein aggregates) via p62 are particularly important for protein and organelle quality control.

Chapter 9: Inflammation in Skeletal Muscle

Muscle as Both an Immune Target and an Endocrine Organ

Inflammation in skeletal muscle is a double-edged sword. Acute inflammatory responses — initiated by damage to muscle fibers during intense exercise or injury, orchestrated by resident and infiltrating immune cells, and resolved through a precisely timed sequence of pro- and anti-inflammatory phases — are essential for muscle repair and hypertrophy. Chronic, low-grade inflammation — characteristic of aging, obesity, type 2 diabetes, and many chronic diseases — is a major driver of muscle atrophy, insulin resistance, and impaired satellite cell function. Understanding the distinction between acute adaptive inflammation and chronic maladaptive inflammation is central to understanding the role of inflammation in muscle pathophysiology.

Muscle fibers that are damaged during exercise or injury release damage-associated molecular patterns (DAMPs) — endogenous danger signals including ATP, HMGB1 (high-mobility group box 1 protein), heat shock proteins, and mitochondrial DNA — that activate pattern recognition receptors (toll-like receptors, particularly TLR4; inflammasome NLRP3) on local innate immune cells (macrophages, mast cells) and on the muscle fibers themselves. This innate immune activation triggers the rapid secretion of pro-inflammatory cytokines — TNF-alpha, IL-1beta, IL-6, and IL-8 — that recruit neutrophils (within hours) and monocyte-derived macrophages (within 1–2 days) to the site of damage. Neutrophils clear debris through phagocytosis and oxidative burst but also cause bystander tissue damage through neutrophil extracellular trap (NET) formation and reactive oxygen species release, which can amplify the initial injury.

Macrophage phenotypic transitions are central to the orderly progression from inflammatory to reparative phases of muscle healing. Early-infiltrating macrophages adopt an M1-like pro-inflammatory phenotype (activated by IFN-gamma and the DAMPs released from necrotic fibers), phagocytosing necrotic debris and sustaining the inflammatory environment that recruits additional macrophages and activates satellite cells. Over 2–4 days, macrophages transition to an M2-like anti-inflammatory phenotype (activated by IL-4, IL-13, and IL-10), secreting IGF-1, TGF-beta, and VEGF that promote satellite cell differentiation, myotube formation, extracellular matrix remodeling, and angiogenesis. Impairment of this M1-to-M2 transition — by persistent infection, chronic systemic inflammation, or aging (which biases macrophage polarization toward sustained M1 activation) — delays muscle repair and promotes fibrosis (TGF-beta-driven collagen deposition by myofibroblasts that fills the repair site instead of regenerating muscle).

Skeletal muscle as an endocrine organ — producing and secreting proteins that act on distant tissues — is a concept that has transformed understanding of the systemic effects of exercise and muscle wasting. Myokines are cytokines and other signaling proteins secreted by contracting skeletal muscle that exert autocrine, paracrine, and endocrine effects. The best-characterized myokine is IL-6, which is released by contracting skeletal muscle in large amounts (rising 10–100-fold in the blood during prolonged exercise) and acts on liver to stimulate glucose output and fat mobilization, on adipose tissue to promote lipolysis, and on immune cells to promote anti-inflammatory M2 polarization. The exercise-induced IL-6 signal is distinct from the inflammatory IL-6 signal produced by macrophages in obesity and chronic disease: exercise-derived IL-6 is released in the absence of TNF-alpha and activates anti-inflammatory rather than pro-inflammatory cascades. Other important myokines include irisin (derived from FNDC5, a membrane protein cleaved and secreted during exercise; acts on adipose tissue to promote browning and on bone to promote osteogenesis), BDNF (brain-derived neurotrophic factor, which promotes neuroplasticity and fat oxidation), FGF21 (which promotes fatty acid oxidation and glucose uptake), and meteorin-like (METRNL) (which promotes adipose browning and anti-inflammatory macrophage polarization).

Signaling Pathways Controlling Muscle Mass

The molecular regulation of skeletal muscle mass is governed by competing anabolic and catabolic signaling cascades that integrate information about nutrient availability, mechanical loading, hormonal status, and inflammatory state to produce coordinated changes in protein synthesis and degradation rates.

The IGF-1/PI3K/Akt/mTORC1 pathway is the primary anabolic signaling cascade in skeletal muscle. IGF-1 (produced locally in muscle and delivered from the liver via the circulation) binds its receptor tyrosine kinase (IGF-1R), leading to autophosphorylation and recruitment of IRS-1 (insulin receptor substrate 1), which is phosphorylated on tyrosine residues that serve as docking sites for the p85 regulatory subunit of PI3K. PI3K generates PIP3 (phosphatidylinositol-3,4,5-trisphosphate) at the plasma membrane, which recruits PDK1 and Akt (via Akt’s PH domain) to the membrane, where Akt is phosphorylated and activated by PDK1 at Thr308 and by mTORC2 at Ser473. Activated Akt then phosphorylates and activates mTORC1 indirectly — by phosphorylating and inhibiting the TSC1/TSC2 complex (which is a GAP for the small GTPase Rheb), allowing Rheb-GTP to activate mTORC1.

mTORC1 (mechanistic target of rapamycin complex 1) is the central integrator of anabolic signals — growth factors (via Akt), nutrients (amino acids, particularly leucine, via the Ragulator-Rag GTPase system at the lysosomal membrane), and energy status (AMPK, which activates TSC2 and directly inhibits mTORC1 via phosphorylation of Raptor). mTORC1 promotes anabolism by phosphorylating p70S6K1 (which activates ribosomal protein S6 and eIF4B to promote ribosome biogenesis and cap-dependent translation) and 4E-BP1 (whose phosphorylation releases it from eIF4E, allowing cap-dependent translation initiation). mTORC1 simultaneously inhibits autophagy by phosphorylating and inhibiting ULK1. The result is a coordinated promotion of protein synthesis and inhibition of protein degradation — the anabolic state required for muscle growth.

The myostatin/ActRIIB/Smad2/3 pathway is the primary negative regulator of muscle growth. Myostatin (GDF8) — a TGF-beta family member — binds the activin receptor type IIB (ActRIIB) on the muscle fiber surface, activating the type I receptor ALK4/5, which phosphorylates SMAD2 and SMAD3 transcription factors. SMAD2/3 translocate to the nucleus and drive expression of PTEN (which reduces PIP3 and inhibits Akt), FoxO transcription factors (driving atrogene expression), and inhibitors of myoblast differentiation — collectively inhibiting both protein synthesis and satellite cell differentiation. Loss-of-function mutations in myostatin — first discovered in the Belgian Blue cattle breed (which has extraordinary muscling due to a myostatin deletion mutation) and subsequently found in whippet dogs (where heterozygous mutations produce “bully whippets” with extreme muscularity) and in rare human cases — demonstrate the extraordinary degree to which myostatin limits muscle mass.

The therapeutic targeting of the myostatin pathway for sarcopenia and muscular dystrophy has been extensively pursued. Agents including anti-myostatin antibodies (trevogrumab, landogrozumab), soluble activin receptor decoys (ACE-031, ACE-083), and the modified activin receptor antibody-peptide fusion bimagrumab have been tested in clinical trials. Bimagrumab (which blocks both myostatin and activin A signaling through ActRIIB) demonstrated in a phase 2 trial in patients with sarcopenia a significant increase in lean mass and reduction in fat mass, but without improvement in the primary functional endpoint (gait speed) — illustrating the translation gap between muscle mass and function in clinical trials of anabolic agents.

Exercise training is the most potent and evidence-based intervention for promoting muscle hypertrophy and counteracting sarcopenia. Resistance exercise activates mTORC1 through both mechanical signaling pathways (including integrin-linked kinase, FAK, and the phospholipase D/PA/mTOR axis) and by stimulating local IGF-1 production. Endurance exercise activates AMPK, driving PGC-1alpha nuclear translocation and mitochondrial biogenesis. The combination of resistance and endurance training — concurrent training — produces benefits across both strength and aerobic capacity but may involve some attenuation of hypertrophic adaptations due to AMPK-mediated inhibition of mTORC1. Understanding the molecular basis of these training adaptations allows for rational exercise prescription aimed at maximizing specific outcomes — muscle hypertrophy, oxidative capacity, mitophagy-mediated quality control — in older adults, disease populations, and athletes.